Get startedLog in
    Picture of Zealand Pharma A/S logo

    ZEAL — Zealand Pharma A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapNeutral
    All News

    Brief: Zealand Pharma, Roche To Advance petrelintide To Phase 3 Trials For Chronic Weight Management

    Picture of Zealand Pharma A/S logoZealand Pharma A/S
    29/04/2026 18:35
    April 29 (Reuters) - Zealand Pharma A/S ZELA.CO:

ZEALAND PHARMA AND ROCHE TO ADVANCE PETRELINTIDE, AN AMYLIN ANALOG, TO PHASE 3 TRIALS FOR CHRONIC WEIGHT MANAGEMENT

ZEALAND PHARMA AND ROCHE TO ADVANCE PETRELINTIDE, AN AMYLIN ANALOG, TO PHASE 3 TRIALS FOR CHRONIC WEIGHT MANAGEMENT

ZEALAND PHARMA - PHASE 2 TRIAL OF PETRELINTIDE AND ENICEPATIDE COMBINATION PLANNED FOR INITIATION IN Q2 2026

ZEALAND PHARMA - PETRELINTIDE DEMONSTRATED DOUBLE-DIGIT WEIGHT LOSS WITH PLACEBO-LIKE TOLERABILITY IN ZUPREME-1 PHASE 2 TRIAL

Source text: ID:nGNX7tyWtW

Further company coverage: ZELA.CO

 ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Zealand Pharma A/S

    See all news